Eng Heather, Sharma Raman, Wolford Angela, Di Li, Ruggeri Roger B, Buckbinder Leonard, Conn Edward L, Dalvie Deepak K, Kalgutkar Amit S
Pharmacokinetics, Pharmacodynamics, and Metabolism Department, Pfizer Inc., Groton, Connecticut (H.E., R.S., A.W., L.D.); Pharmacokinetics, Pharmacodynamics, and Metabolism Department, Pfizer Inc., La Jolla, California (D.K.D.); Pharmacokinetics, Pharmacodynamics, and Metabolism Department (A.S.K.), Worldwide Medicinal Chemistry (E.L.C., R.B.R.), and Cardiovascular and Metabolic Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts.
Pharmacokinetics, Pharmacodynamics, and Metabolism Department, Pfizer Inc., Groton, Connecticut (H.E., R.S., A.W., L.D.); Pharmacokinetics, Pharmacodynamics, and Metabolism Department, Pfizer Inc., La Jolla, California (D.K.D.); Pharmacokinetics, Pharmacodynamics, and Metabolism Department (A.S.K.), Worldwide Medicinal Chemistry (E.L.C., R.B.R.), and Cardiovascular and Metabolic Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts
Drug Metab Dispos. 2016 Aug;44(8):1262-9. doi: 10.1124/dmd.116.070185. Epub 2016 Apr 14.
N1-Substituted-6-arylthiouracils, represented by compound 1 [6-(2,4-dimethoxyphenyl)-1-(2-hydroxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one], are a novel class of selective irreversible inhibitors of human myeloperoxidase. The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean ± S.D.] = 8.6 ± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 ± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes). The in vitro metabolic instability also manifested in moderate-to-high plasma clearances of the parent compound in rats and dogs with significant concentrations of M1 detected in circulation. Mild heat deactivation of liver microsomes or coincubation with the flavin-containing monooxygenase (FMO) inhibitor imipramine significantly diminished M1 formation. In contrast, oxidative metabolism of compound 1 to M1 was not inhibited by the pan cytochrome P450 inactivator 1-aminobenzotriazole. Incubations with recombinant FMO isoforms (FMO1, FMO3, and FMO5) revealed that FMO1 principally catalyzed the conversion of compound 1 to M1. FMO1 is not expressed in adult human liver, which rationalizes the species difference in oxidative desulfurization. Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 μM, 20.4 nmol/min/mg protein, and 82.7 μl/min/mg protein, respectively. Addition of excess glutathione essentially eliminated the conversion of compound 1 to M1 in NADPH-supplemented rat and dog liver microsomes, which suggests that the initial FMO1-mediated S-oxygenation of compound 1 yields a sulfenic acid intermediate capable of redox cycling to the parent compound in a glutathione-dependent fashion or undergoing further oxidation to a more electrophilic sulfinic acid species that is trapped intramolecularly by the pendant alcohol motif in compound 1.
以化合物1[6-(2,4-二甲氧基苯基)-1-(2-羟乙基)-2-硫代-2,3-二氢嘧啶-4(1H)-酮]为代表的N1-取代-6-芳基硫脲是一类新型的人髓过氧化物酶选择性不可逆抑制剂。本报告总结了我们的体外研究,该研究表明在补充NADPH的大鼠(半衰期[t1/2 =平均值±标准差]=8.6±0.4分钟)和犬肝微粒体(t1/2 = 11.2±0.4分钟)中,化合物1可轻易氧化脱硫生成环醚代谢物M1[5-(2,4-二甲氧基苯基)-2,3-二氢-7H-恶唑并[3,2-a]嘧啶-7-酮],但在人肝微粒体中则不然(t1/2>120分钟)。体外代谢不稳定性还表现为大鼠和犬体内母体化合物的血浆清除率适中至高,且循环中检测到显著浓度的M1。肝微粒体轻度热失活或与含黄素单加氧酶(FMO)抑制剂丙咪嗪共同孵育可显著减少M1的形成。相比之下,化合物1氧化代谢生成M1不受泛细胞色素P450失活剂1-氨基苯并三唑的抑制。与重组FMO同工型(FMO1、FMO3和FMO5)共同孵育表明,FMO1主要催化化合物1转化为M1。FMO1在成人肝脏中不表达,这解释了氧化脱硫的种属差异。FMO1催化的氧化反应遵循米氏动力学,米氏常数、最大氧化脱硫速率和内在清除率值分别为209μM、20.4 nmol/min/mg蛋白和82.7μl/min/mg蛋白。在补充NADPH的大鼠和犬肝微粒体中加入过量谷胱甘肽基本上消除了化合物1向M1的转化,这表明FMO1介导的化合物1的初始S-氧化产生了一种亚磺酸中间体,该中间体能够以谷胱甘肽依赖的方式氧化还原循环回母体化合物,或进一步氧化为更具亲电性的亚磺酸物种,该物种被化合物1中的侧链醇基序分子内捕获。